350 research outputs found
Noninvasive treatment for ingrown nails: Anchor taping, acrylic affixed gutter splint, sculptured nail and others.
No full textActualidad literaria hispanoargelina (II): la reciente obra de Souad Hadj-Ali Mouhoub
No full textBibliographical commentary on three works by the Algerian author Souad Hadj-Ali Mouhoub.Comentario bibliográfico sobre tres obras de la autora argelina Souad Hadj-Ali Mouhoub
Abstract 3407: Side effects of BRAF inhibitors mimic RASopathies
No full textAbstract
Recent advances in targeted anticancer therapies have substantially improved the prognosis of several cancers but they are not free of side effects. These side effects are, however, clearly distinct from those induced by classical cytotoxic chemotherapies, likely because targeted therapies are designed to interfere with specific oncogenic signaling pathways and not to inhibit cell proliferation in general. We, therefore, evaluated whether specific side effects of BRAF inhibitor therapies would resemble symptoms seen in patients with RASopathies, in which the MAPK pathway is affected and which includes Costello, Noonan and Cardio-Facio-Cutaneous syndromes. To this end, we collected a cohort of 18 patients with genetically confirmed RASopathies that were followed between 2012 and 2016 at the University Hospital of Rennes, France and that were evaluated based on their personal medical history and a clinical examination. Strikingly, RASopathy patients, particularly those with Cardio-Facio-Cutaneous syndrome, showed symptoms resembling those that we and others have previously seen in genetically characterized patients undergoing BRAF inhibitor treatment. These symptoms included keratosis pilaris, wavy hair, sparse eyelashes/eyebrows, poor hair growth, palmo-plantar hyperkeratosis in areas of pressure, verrucous papillomas, nevi efflorescence, and increased cancer risk. Nevertheless, BRAF-inhibitor treatment can also lead to side effects not typically found in patients with RASopathies, including acneiform dermatitis and vemurafenib-specific phototoxicity, which may even increase under a combined BRAF/MEK inhibition. These results suggest that the side effects of BRAF inhibition that are similar to symptoms in patients with RASopathies are due to direct targeting of the MAPK pathway in BRAF-non-mutated (wild type) cells while those that are dissimilar represent off-target effects that do not affect the MAPK pathway. We hope that this type of comparative analysis may lead to a better understanding of the multiple effects of targeted therapies and perhaps prompt modifications in the targeted therapy approach to minimize these side effects.
Citation Format: Alicia Sfecci, Alain Dupuy, Monica Dinulescu, Catherine Droitcourt, Henri Adamski, Smail Hadj-Rabia, Sylvie Odent, Marie-Dominique Galibert, Lise Boussemart. Side effects of BRAF inhibitors mimic RASopathies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3407. doi:10.1158/1538-7445.AM2017-3407</jats:p
ICHTYOSES SYNDROMIQUES (ETUDE CLINIQUE ET IDENTIFICATION D'UNE NOUVELLE FORME LIEE AU CHROMOSOME 3 (DES DERMATOLOGIE VENEREOLOGIE))
No full textPARIS12-CRETEIL BU Médecine (940282101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
La rabia en Filúmeno de Alejandría
No full textThe aim of this paper is to summarize and to comment about the text which Philumenus of Alexandria collects about rabies in the first chapters of his treatise De venenatis animalibus eorumque remediis. After a very short review of the literary precedents about this topic, the author analyzes the pharmacologic, chirurgical and dietetic remedies, highlighting the work of Philumenus as the main source on rabies for the authors of the forthcoming centuries.El objetivo del presente artículo es resumir y comentar el texto sobre la enfermedad de la rabia que Filúmeno de Alejandría recoge en los primeros capítulos de su tratado De venenatis animalibus eorumque remediis. Tras mencionar los precedentes literarios sobre este tema, se analiza los remedios farmacológicos, quirúrgicos y dietéticos, destacando la importancia de la obra de Filúmeno como fuente principal sobre esta enfermedad para los autores de los siglos posteriores
VARIATIONS PHYSIOLOGIQUES DU FACTEUR VON WILLEBRAND CHEZ LES DONNEURS DE SANG AU CHU DE TIZI-OUZOU
No full textLe facteur Von Willebrand (VWF) est une glycoprotéine qui joue un rôle crucial dans
l’hémostase, il connait de fortes variations physiologiques qui sont attribuées à de nombreux
facteurs tant génétiques qu’environnementaux.
L’objectif de notre travail est d’identifier ces derniers et de préciser les variations du facteur
de Von Willebrand, l’étude menée chez 68 donneurs de sang (avec un sex-ratio égal à 2,08)
au CHU Nedir Mohamed pour le dosage du VWF par une technique de référence (dosage de
l’activité du cofacteur de la ristocétine).
Les résultats obtenus ont montré que les taux plasmatiques moyens étaient relativement plus
élevés chez les donneurs de sang (>150%) comparés aux valeurs de références
internationales comprises entre [50-150%]. Ces taux étaient significativement plus bas chez
les sujets appartenant au groupe sanguins O (137,53%) par rapport aux autres groupes
(229,26%), et (1,3) fois plus élevés chez les sportifs et chez les fumeurs (212,41%) que chez
les non-fumeurs (116,52%) ; tandis qu’aucune corrélation significative n’a été observée
concernant le sexe (p=0,50), le rhésus D (p=0,7), le stress émotionnel (p=0,40) et la
contraception (p=0,2)
- …
